Internship
Investment firm managing diverse assets
$33.00/hr
Hopkins, MN, USA
Upload your resume to see how it matches 24 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Farallon Capital Management manages both public and private assets for a variety of clients, including institutional investors, high-net-worth individuals, and family offices. The firm uses a detailed bottom-up fundamental analysis to identify investment opportunities and continuously updates its strategies to remain competitive in the market. With 38 years of experience and $39 billion in assets under management, Farallon aims to provide superior risk-adjusted returns to its investors. What sets Farallon apart from its competitors is its focus on aligning the interests of its team, clients, and partners, which fosters a collaborative culture. The firm generates revenue through management fees and performance-based incentives, ensuring that its success is linked to the success of its clients.
Company Size
201-500
Company Stage
N/A
Total Funding
$9.7B
Headquarters
San Francisco, California
Founded
1986
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
Eagle Point and Farallon bought the 115,700-square-foot office and retail building in 2021 for $40.5 million, or $350 per square foot.
Pentera has raised $60 million in a Series D funding round led by Evolution Equity Partners, with additional backing from Farallon Capital Management.
3D Investment Partners and Farallon Capital, holding 32.7% of Fuji Soft, agreed to sell their shares to KKR for 8,800 yen (US$59) each.
When Steyer retired from Farallon in 2012, he said it was in part because he had come to disagree with the hedge fund's big bets on fossil fuels and private prisons.
Cambridge, MA – eGenesis, a biotechnology company developing human-compatible engineered organs to address the global organ shortage, today announced the close of a $191 million Series D financing. Proceeds will be used to advance the company’s lead product candidate, EGEN-2784, to a first-in-human study for kidney transplant. The funding will also be used to advance … Continued